Your browser is no longer supported. Please, upgrade your browser.
Settings
ABIO ARCA biopharma, Inc. daily Stock Chart
ABIO [NASD]
ARCA biopharma, Inc.
Index- P/E- EPS (ttm)-1.81 Insider Own0.80% Shs Outstand9.08M Perf Week1.92%
Market Cap24.07M Forward P/E- EPS next Y- Insider Trans-3.12% Shs Float9.04M Perf Month3.92%
Income-16.40M PEG- EPS next Q- Inst Own69.00% Short Float1.02% Perf Quarter1.92%
Sales- P/S- EPS this Y0.30% Inst Trans-2.67% Short Ratio3.03 Perf Half Y-10.17%
Book/sh2.44 P/B1.09 EPS next Y- ROA-53.50% Target Price16.50 Perf Year-26.80%
Cash/sh2.33 P/C1.14 EPS next 5Y- ROE-57.60% 52W Range2.15 - 4.35 Perf YTD-7.02%
Dividend- P/FCF- EPS past 5Y39.50% ROI- 52W High-39.08% Beta2.21
Dividend %- Quick Ratio9.00 Sales past 5Y- Gross Margin- 52W Low23.26% ATR0.14
Employees20 Current Ratio9.00 Sales Q/Q- Oper. Margin- RSI (14)57.99 Volatility7.13% 5.81%
OptionableNo Debt/Eq0.00 EPS Q/Q-34.00% Profit Margin- Rel Volume1.26 Prev Close2.50
ShortableYes LT Debt/Eq0.00 EarningsMar 30 AMC Payout- Avg Volume30.33K Price2.65
Recom2.00 SMA205.68% SMA503.53% SMA200-2.22% Volume38,319 Change6.00%
Oct-09-13Initiated Dawson James Buy $3.75
Mar-25-17 01:04PM  ARCA BIOPHARMA, INC. Financials
Mar-21-17 04:46PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
04:30PM  ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update Business Wire
04:10PM  ARCA BIOPHARMA, INC. Files SEC form 10-K, Annual Report
Mar-06-17 04:32PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  ARCA biopharma Announces 175th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial Business Wire
Mar-01-17 04:47PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Feb-21-17 08:46AM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
08:30AM  Anders Hove, MD Joins ARCA biopharma Board of Directors Business Wire
Jan-18-17 04:32PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  ARCA biopharma Announces 150th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial Business Wire
Jan-11-17 04:54PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit
Jan-04-17 08:30AM  ARCA biopharma to Present at Biotech Showcase 2017 Business Wire
Dec-20-16 02:26PM  Hedge Funds Arent Crazy About A. M. Castle & Co (CASL) Anymore at Insider Monkey +10.64%
Nov-15-16 08:30AM  StockNewsNow.com Publishes New SNNLive Video Interview with ARCA biopharma, Inc. Provides Company Overview and Discusses Clinical Development PR Newswire -7.07%
Nov-14-16 05:19PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi +5.32%
05:08PM  ARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report
04:15PM  ARCA biopharma Announces Third Quarter 2016 Financial Results and Provides Business Update Business Wire
Oct-06-16 04:07PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  ARCA biopharma Announces Randomization of First European Patients in GENETIC-AF Phase 2B/3 Clinical Trial Business Wire
Oct-04-16 08:30AM  ARCA biopharma to Present at the Dawson James Securities Second Annual Growth Stock Conference Business Wire
Sep-13-16 09:00AM  ARCA biopharma Named Winner of Corporate LiveWire Healthcare and Lifesciences Innovation Award Business Wire
Aug-18-16 04:16PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  ARCA biopharma Announces 100th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial Business Wire
Aug-09-16 04:37PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
04:30PM  ARCA biopharma Announces Second Quarter 2016 Financial Results and Provides Business Update Business Wire
Aug-03-16 01:37AM  Albioma :ABIO-FR: Earnings Analysis: For the six months ended June 30, 2016 : August 3, 2016
Jun-13-16 05:01PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote o
May-11-16 04:57PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi -5.56%
04:49PM  ARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report
04:30PM  ARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update Business Wire
Apr-18-16 04:31PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:00AM  ARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial Business Wire
Mar-17-16 04:44PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
04:30PM  ARCA biopharma Announces Fiscal Year 2015 Financial Results and Provides Business Update Business Wire
04:14PM  ARCA BIOPHARMA, INC. Files SEC form 10-K, Annual Report
02:25PM  Bearish case for Valeant
Mar-07-16 04:32PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit
Feb-16-16 04:41PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jan-12-16 08:46AM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -13.10%
08:30AM  GENETIC-AF Clinical Trial for Prevention of Atrial Fibrillation Enrolls 50th Patient Business Wire
Dec-08-15 09:00AM  Applying Lessons from KBIO Accesswire
Nov-30-15 09:38AM  2 Micro-Cap Opportunities in Atrial Fibrillation Accesswire
Nov-23-15 03:07PM  Biotechs Under 20 Dollars Poised to Breakout Accesswire +8.75%
Nov-19-15 08:30AM  ARCA biopharma to Present at the 27th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-18-15 09:42AM  2 Important Takeaways from ARCA Biopharma's Q3 Results Accesswire
Nov-12-15 04:43PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
04:30PM  ARCA biopharma Announces Third Quarter 2015 Financial Results and Provides Business Update Business Wire
Nov-05-15 08:30AM  ARCA biopharma CEO Michael Bristow to Present in Two Sessions at the American Heart Association Scientific Sessions 2015 Business Wire
Nov-04-15 07:47AM  4 Stocks Under $10 Making Big Up Moves on Big Volume at TheStreet
Oct-20-15 02:08PM  Venrocks Latest Pick Shows There Are More Biotech Opportunities to Explore at Insider Monkey
Oct-19-15 09:28AM  Biotech Pullback: Look to Targeted Therapy Companies Accesswire
Oct-06-15 03:01PM  Biotechs take a beating
Sep-15-15 11:20AM  ARCA biopharma (ABIO): Leveraging Genetic Targeting to Better Treat Cardiovascular Disease Accesswire
Sep-09-15 04:06PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:00AM  Gencaro Potential Efficacy Preventing Atrial Flutter in Heart Failure Paper to Be Presented at 2015 HFSA Annual Scientific Meeting Business Wire
Sep-03-15 04:32PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial S
Aug-26-15 08:30AM  ARCA biopharma to Present at the Rodman & Renshaw 17th Annual Global Investment Conference Business Wire
Aug-13-15 08:10PM  10-Q for ARCA biopharma, Inc. at Company Spotlight
12:05PM  3 Promising Plays in Healthcare's Most Vibrant Space
Aug-11-15 04:18PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
04:00PM  ARCA biopharma Announces Second Quarter 2015 Operating Results and Provides Update on Recent Accomplishments Business Wire
Jul-16-15 05:01PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standa -10.37%
Jun-29-15 10:27AM  Nutritional Supplement Industry Flexes its Muscles as Natural & Pharmaceutical Supplement Products Continue to Hit the Market - Company Prepares for Strong Revenue Growth in 2nd Half of 2015 PR Newswire
09:15AM  RA Capital Is Expecting A Breakthrough Cancer Drug From This Biotech at Insider Monkey
Jun-23-15 04:37PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-17-15 09:00AM  ARCA biopharma Announces Closing of $37 Million Private Placement Business Wire -5.32%
Jun-11-15 05:11PM  ARCA BIOPHARMA, INC. Files SEC form 8-K/A, Financial Statements and Exhibits +7.23%
08:56AM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secu
08:50AM  ARCA biopharma Announces $37 Million Private Placement
Jun-05-15 05:00PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events
May-14-15 08:11PM  10-Q for ARCA biopharma, Inc. at Company Spotlight
May-12-15 04:44PM  ARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report
May-02-15 08:09PM  10-K for ARCA biopharma, Inc. at Company Spotlight
Apr-14-15 04:00PM  ARCA biopharma Gains on Fast Track Status for Gencaro - Analyst Blog
Apr-13-15 04:45PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +13.10%
02:47PM  ARCA biopharma (ABIO) Stock Surges Today on FDA Fast Track Designation at TheStreet
08:30AM  ARCA biopharma Receives FDA Fast Track Designation for Gencaro Atrial Fibrillation Development in a Genetically Targeted Heart Failure Population Business Wire
Mar-20-15 05:38AM  ARCA biopharma Provides GENETIC-AF Clinical Trial Update at noodls
Mar-19-15 04:58PM  ARCA BIOPHARMA, INC. Files SEC form 10-K, Annual Report
Mar-16-15 05:03PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:30PM  ARCA biopharma Provides GENETIC-AF Clinical Trial Update Business Wire
Mar-05-15 01:42PM  3 Biotech stocks Under $10 to Trade for Breakouts at TheStreet
Feb-23-15 04:51PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standa
Feb-17-15 05:11PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Feb-04-15 04:36PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  ARCA biopharma Announces Patent Issuance for Methods and Compositions of S-isomer Formulation of Gencaro Business Wire
Dec-30-14 04:37PM  ARCA BIOPHARMA, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers, Financial Statements and Exhibi
Dec-11-14 05:11PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  Arca biopharma Announces Activation of First Canadian Genetic-AF Clinical Trial Site Business Wire
Dec-10-14 05:13PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  ARCA biopharma Receives FDA Orphan Drug Designation for rNAPc2 as a Potential Treatment for Ebola Business Wire
Dec-01-14 05:28PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online
05:00PM  ARCA biopharma Announces Management Transitions Business Wire
Nov-14-14 07:09PM  10-Q for ARCA biopharma, Inc. Company Spotlight
Nov-12-14 05:14PM  ARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
Sep-16-14 08:00AM  LabCorp/ARCA biopharma GENETIC-AF Poster Presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America Business Wire
Sep-08-14 08:30AM  LabCorp/ARCA biopharma GENETIC-AF Poster Selected for Presentation at the 18th Annual Scientific Meeting of the Heart Failure Society of America Business Wire
Aug-18-14 04:18PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
08:30AM  ARCA biopharma Announces Health Canada Acceptance of Genetic-AF Clinical Trial Application Business Wire
ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in patients with heart failure and left ventricular with reduced left ventricular ejection fraction. The company also engages in developing recombinant Nematode Anticoagulation Protein c2, a therapy for the disease syndrome caused by infection from hemorrhagic fever viruses and other pathogens. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B/Phase 3 clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ozeroff Christopher DavidS.V.P., General CounselFeb 28Sale2.614651,21417,935Mar 01 05:11 PM
Keuer Thomas AChief Operating OfficerFeb 28Sale2.614651,21414,435Mar 01 05:11 PM
BRISTOW MICHAEL RPres. & Chief Executive OfficFeb 28Sale2.617631,99141,875Mar 01 05:10 PM
Selby Brian L.VP, FinanceFeb 27Sale2.561614122,389Mar 01 05:12 PM
Keuer Thomas AChief Operating OfficerOct 18Sale2.454831,18414,900Oct 18 04:30 PM
Keuer Thomas AChief Operating OfficerSep 20Sale2.897142,06315,383Sep 21 04:08 PM
BRISTOW MICHAEL RPres. & Chief Executive OfficSep 20Sale2.891,9725,69942,638Sep 21 04:09 PM
Ozeroff Christopher DavidS.V.P., General CounselSep 20Sale2.891,1853,42518,400Sep 21 04:07 PM
Selby Brian L.VP, FinanceSep 19Sale2.914761,3852,550Sep 21 04:06 PM
BRISTOW MICHAEL RSee RemarksApr 05Sale3.527242,54844,610Apr 06 05:02 PM
Keuer Thomas AChief Operating OfficerApr 05Sale3.523841,35216,097Apr 06 05:01 PM
Ozeroff Christopher DavidS.V.P., General CounselApr 05Sale3.523661,28819,585Apr 06 05:01 PM
Selby Brian L.VP, FinanceApr 04Sale3.521,1143,9213,026Apr 06 05:00 PM